Navigation Links
TGen and Scottsdale Healthcare begin study of new drug for patients with solid tumors
Date:6/17/2014

SCOTTSDALE, Ariz. June 17, 2014 The Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) are studying the safety and effectiveness of a new drug, AG-120, for treatment of patients with solid tumors, especially those with brain tumors and gallbladder bile duct cancer.

"AG-120 is designed specifically for those patients who carry the IDH1 gene mutation," said Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-In-Chief at TGen, and Chief Scientific Officer for the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and TGen that delivers new treatments to cancer patients based on precision medicine.

The IDH1 gene mutation is most commonly found in gliomas, which make up the largest group of "primary" brain tumors, those that start in the brain. Gliomas include all tumors arising from the gluey or supportive tissue of the brain. They represent about 30 percent of all brain tumors, and about 80 percent of all malignant brain tumors.

As with all brain cancers, gliomas are difficult to treat and many grow back after surgery, radiation and standard of care chemotherapy. Many drugs cannot get to the brain because of a filtering mechanism in the body called the blood-brain barrier.

"There is a great need for more effective treatments for patients with gliomas and other solid tumors, such as gallbladder bile duct cancer," said Dr. Von Hoff, who is the Principal Investigator for AG-120 clinical trial. This study will enroll as many as 50 patients. Researchers will use precision medicine to match treatments to patient's specific genomic, or molecular, makeups.

Mutations in isocitrate dehydrogenase (IDH) 1 and 2, originally discovered in 2008, occur in the vast majority of low-grade gliomas and secondary high-grade gliomas. IDH mutations are oncogenic, meaning they have the potential to cause cancer. These mutations occur early in the formation of gliomas and in gallbladder bile duct cancer.

AG-120 is produced by Agios Pharmaceuticals Inc., based in Cambridge, Mass.

IDH1 is a metabolic enzyme identified by Agios as a protein that is mutated in a wide range of malignant tumors. Agios and its collaborators recently demonstrated that IDH1 mutations initiate and drive cancer growth by blocking differentiation, or maturation, of primitive cells. According to Agios, the inhibition of these mutated proteins may lead to clinical benefit for those cancer patients whose tumors carry them.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen and Scottsdale Healthcare cancer expert Dr. Von Hoff receives Hope Funds award
2. TGen and Scottsdale Healthcare cancer expert Dr. Daniel D. Von Hoff is honored by ASCO
3. Scottsdale Treatment Center Launches Program to Address Illicit Drug Use in Adults, Adolescents
4. Home Care Assistance of Scottsdale Launches New Website
5. Luxury Arizona Condos from The Statesman Group are Now Available for Purchase in Scottsdale/Phoenix, Arizona
6. Top Phoenix Hearing Aid Provider Opens New Office in Scottsdale, AZ
7. Younan Properties Announces Successful Financing of Scottsdale Shopping Center; Retail Promenade to be Renamed 7 Thousand Shea
8. Alice Branton Invites the Eyes of the World to Focus on Scottsdale, Arizona
9. Arizona Marijuana Doctor Helps Scottsdale Patients Achieve Green Wellness in the Copper State
10. Mahendra Kumar Trivedi to Host Retreat in Scottsdale, Arizona
11. TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of proteomic mapping
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2018)... ... ... Oak Street Health , a network of health centers providing a ... center to its Chicago operations. With the addition of Little Village, Oak Street Health ... providing care for adults on Medicare in areas where health care is needed most. ...
(Date:9/24/2018)... ... 2018 , ... A device that more than 80 percent ... for soldiers suffering from traumatic brain injuries (TBI) and infectious diseases, thanks to ... researchers are developing machine learning algorithms that will sort through a host of ...
(Date:9/22/2018)... (PRWEB) , ... September 21, 2018 , ... Liz Dudek, ... at the Sept. 25 Hillsborough County Chapter meeting of the Florida Assisted Living Association ... Brandon, Florida. , Dudek’s presentation will provide an overview of the success of ...
(Date:9/22/2018)... ... September 22, 2018 , ... Nonprofit and not-for-profit organizations ... different categories listed in section 501(c) of the Internal Revenue Code under which ... as a 501(c)(3)), private foundations, political organizations, and others such as chambers of ...
(Date:9/15/2018)... (PRWEB) , ... September 14, 2018 , ... ... includes, among other funding, full FY 2019 appropriations for Labor, Health and Human ... funding for the evidence-based Teen Pregnancy Prevention (TPP) Program, and $286.5 million for ...
Breaking Medicine News(10 mins):
(Date:9/12/2018)... ... September 13, 2018 , ... Donaldson Plastic Surgery has been included on ... Business First's Fast 50 list of central Ohio's fastest growing businesses. The plastic surgery ... of 81 percent. It is the only medical practice and plastic surgery office to ...
(Date:9/7/2018)... FOLSOM, Calif. (PRWEB) , ... September 06, 2018 , ... ... Best Overall Scientific Paper Award for his presentation of: IDEAL IMPLANT® - Seven-Year Clinical ... asked to present the paper again at the upcoming ASPS (American Society of Plastic ...
(Date:9/7/2018)... ... 07, 2018 , ... New York City is currently the epicenter of the ... of claiming the fourth and final jewel in the 2018 grand slam crown – ... Seldom, however, will the players’ footwork be highlighted. , “Today’s tennis isn’t that of ...
Breaking Medicine Technology: